BridgeBio Pharma (2CL) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2CL Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

BridgeBio

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2CL Stock 12 Month Forecast

Average Price Target

€95.50

▲(41.75% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is €95.50 with a high forecast of €135.50 and a low forecast of €81.13. The average price target represents a 41.75% change from the last price of €67.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"€42","89":"€89","136":"€136","65.5":"€65.5","112.5":"€112.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135.50042,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€135.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.4950505882353,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€95.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.12764,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€81.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,65.5,89,112.5,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.12,71.45695538461538,76.79391076923078,82.13086615384616,87.46782153846154,92.80477692307693,98.14173230769231,103.47868769230769,108.81564307692307,114.15259846153846,119.48955384615384,124.82650923076923,130.1634646153846,{"y":135.50042,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.12,68.3796192760181,70.6392385520362,72.8988578280543,75.1584771040724,77.4180963800905,79.6777156561086,81.9373349321267,84.1969542081448,86.4565734841629,88.716192760181,90.9758120361991,93.2354313122172,{"y":95.4950505882353,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.12,67.27443384615385,68.42886769230769,69.58330153846154,70.73773538461539,71.89216923076923,73.04660307692308,74.20103692307693,75.35547076923078,76.50990461538461,77.66433846153846,78.81877230769231,79.97320615384615,{"y":81.12764,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.37,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.12,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€135.50

Average Price Target€95.50

Lowest Price Target€81.13

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

€112.2

Buy

66.54%

Upside

Reiterated

09/14/26

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Ram Selvaraju

H.C. Wainwright

€94.94→€103.57

Buy

53.73%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO), EyePoint Pharmaceuticals (NASDAQ: EYPT) and Abbott Laboratories (NYSE: ABT)

Andrew Tsai

Jefferies

€94.94

Buy

40.92%

Upside

Reiterated

08/31/26

Jefferies Remains a Buy on BridgeBio Pharma (BBIO)

Biren Amin

Piper Sandler

€99.25

Buy

47.32%

Upside

Reiterated

08/31/26

Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Eliana Merle

Barclays

€135.5

Buy

101.13%

Upside

Reiterated

08/31/26

Barclays Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Salim Syed

Mizuho Securities

€82.85→€94.94

Buy

40.92%

Upside

Reiterated

08/31/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)

Joshua Schimmer

Cantor Fitzgerald

€94.94

Buy

40.92%

Upside

Reiterated

08/29/26

Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)

Luca Issi

RBC Capital

€86.31

Buy

28.11%

Upside

Reiterated

08/14/26

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)

Anupam Rama

J.P. Morgan

€86.31→€95.8

Buy

42.20%

Upside

Assigned

08/12/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)

Whitney Ijem

Canaccord Genuity

€89.76→€91.48

Buy

35.79%

Upside

Reiterated

08/12/26

Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)

Danielle Brill

Truist Financial

€88.03→€92.35

Buy

37.07%

Upside

Reiterated

08/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eric Joseph

Citi

€80.26→€81.13

Hold

20.42%

Upside

Reiterated

08/12/26

BridgeBio Pharma (BBIO) Gets a Hold from Citi

Tyler Van Buren

TD Cowen

€81.99→€94.94

Buy

40.92%

Upside

Assigned

08/11/26

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/11/26

BridgeBio Earns Buy Rating on Attruby Outperformance and Multibillion-Dollar Growth Visibility

Derek Archila

Wells Fargo

€84.58→€88.03

Buy

30.67%

Upside

Reiterated

08/11/26

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

€112.2

Buy

66.54%

Upside

Reiterated

09/14/26

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Ram Selvaraju

H.C. Wainwright

€94.94→€103.57

Buy

53.73%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO), EyePoint Pharmaceuticals (NASDAQ: EYPT) and Abbott Laboratories (NYSE: ABT)

Andrew Tsai

Jefferies

€94.94

Buy

40.92%

Upside

Reiterated

08/31/26

Jefferies Remains a Buy on BridgeBio Pharma (BBIO)

Biren Amin

Piper Sandler

€99.25

Buy

47.32%

Upside

Reiterated

08/31/26

Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Eliana Merle

Barclays

€135.5

Buy

101.13%

Upside

Reiterated

08/31/26

Barclays Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Salim Syed

Mizuho Securities

€82.85→€94.94

Buy

40.92%

Upside

Reiterated

08/31/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)

Joshua Schimmer

Cantor Fitzgerald

€94.94

Buy

40.92%

Upside

Reiterated

08/29/26

Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)

Luca Issi

RBC Capital

€86.31

Buy

28.11%

Upside

Reiterated

08/14/26

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)

Anupam Rama

J.P. Morgan

€86.31→€95.8

Buy

42.20%

Upside

Assigned

08/12/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)

Whitney Ijem

Canaccord Genuity

€89.76→€91.48

Buy

35.79%

Upside

Reiterated

08/12/26

Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)

Danielle Brill

Truist Financial

€88.03→€92.35

Buy

37.07%

Upside

Reiterated

08/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eric Joseph

Citi

€80.26→€81.13

Hold

20.42%

Upside

Reiterated

08/12/26

BridgeBio Pharma (BBIO) Gets a Hold from Citi

Tyler Van Buren

TD Cowen

€81.99→€94.94

Buy

40.92%

Upside

Assigned

08/11/26

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/11/26

BridgeBio Earns Buy Rating on Attruby Outperformance and Multibillion-Dollar Growth Visibility

Derek Archila

Wells Fargo

€84.58→€88.03

Buy

30.67%

Upside

Reiterated

08/11/26

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARWRArrowhead Pharmaceuticals

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

AXGNAxoGen

HITIHigh Tide

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

3 Months

Biren AminPiper Sandler

Success Rate

14/21 ratings generated profit

Average Return

+11.26%

Copying Biren Amin's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.26% per trade.

1 Year

Jason ZemanskyBank of America Securities

Success Rate

20/23 ratings generated profit

Average Return

+55.06%

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +55.06% per trade.

2 Years

Anupam RamaJ.P. Morgan

Success Rate

23/26 ratings generated profit

Average Return

+102.78%

Copying Anupam Rama's trades and holding each position for 2 Years would result in 88.46% of your transactions generating a profit, with an average return of +102.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2CL Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2CL has received 33 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2CL average Analyst price target in the past 3 months is 95.50.

Each month's total comprises the sum of three months' worth of ratings.

2CL Financial Forecast

2CL Earnings Forecast

Next quarter’s earnings estimate for 2CL is -€0.53 with a range of -€0.75 to -€0.27. The previous quarter’s EPS was -€0.67. 2CL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2CL has Performed in-line its overall industry.

2CL Sales Forecast

Next quarter’s sales forecast for 2CL is €232.16M with a range of €214.06M to €254.60M. The previous quarter’s sales results were €210.31M. 2CL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2CL has Performed in-line its overall industry.

2CL Stock Forecast FAQ

What is DE:2CL’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 95.50.

What is DE:2CL’s upside potential, based on the analysts’ average price target?

BridgeBio Pharma Inc has 41.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BridgeBio Pharma Inc a Buy, Sell or Hold?

BridgeBio Pharma Inc has a consensus rating of Strong Buy, which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is BridgeBio Pharma Inc’s share price target?

The average share price target for BridgeBio Pharma Inc is 95.50. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €135.50 ,and the lowest forecast is €81.13. The average share price target represents 41.75% Increase from the current price of €67.37.

What do analysts say about BridgeBio Pharma Inc?

BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of BridgeBio Pharma Inc?

To buy shares of DE:2CL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BridgeBio Pharma (2CL) Stock Forecast & Price Target

2CL Analyst Ratings

2CL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Pharma

2CL Analyst Recommendation Trends

2CL Financial Forecast

2CL Earnings Forecast

2CL Sales Forecast

2CL Stock Forecast FAQ

Detailed List of Analyst Forecasts